Health
Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization
VOCAL, an open-label active-controlled study, is being conducted at DaVita dialysis clinics to evaluate benefits of treating patients with Vafseo three times a weekCAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the initiation of a post-marketing study to identify additional potential benefits of Vafseo® (vadadustat). The VOCAL tria
About this update from Davita Inc.
[{"type":"image","alt":"Akebia Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Akebia Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":122,"url":"https://media.zenfs.com/en/globenewswire.com/865d2292021f9ae78a76043efeea8849"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_bsAI2TGvJhraBA7ZLgS7g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/865d2292021f9ae78a76043efeea8849","width":300,"height":122}},"lazy":false},{"type":"text","content":"VOCAL, an open-label active-controlled study, is being conducted at DaVita dialysis clinics to evaluate benefits of treating patients with Vafseo three times a week","length":164,"tagName":"p"},{"type":"text","content":"CAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the initiation of a post-marketing study to identify additional potential benefits of Vafseo® (vadadustat). The VOCAL trial, conducted within DaVita clinics, aims to generate data to evaluate the efficacy and safety of three times per week (TIW) dosing of vadadustat compared to standard of care erythropoiesis-stimulating agents (ESA) in patients with anemia of CKD receiving in-center hemodialysis.","length":614,"tagName":"p"},{"type":"text","content":"“Our team and partners within the dialysis community share a commitment to improving patient care,” said Steven K. Burke, M.D., Chief Medical Officer of Akebia. “The VOCAL trial, conducted within DaVita clinics, enables us to continue building the body of evidence on the effectiveness of Vafseo when dosed three times a week as well as to understand the potential additional benefits of Vafseo treatment for anemia in CKD patients.”","length":433,"tagName":"p"},{"type":"text","content":"The VOCAL trial is expected to enroll approximately 350 patients across 18 DaVita hemodialysis clinics. This open-label trial will employ 1:1 randomization. Patients will participate in the study for up to 33 weeks including screening, treatment and safety follow-up. The primary endpoint of the study is change in hemoglobin, and secondary endpoints include number of patients reporting treatment-emergent serious adverse events, proportion of pati...